Shamburg News · 8-K filed Oct 27, 2026, 4:44 PM EDT
Cardiff Oncology Appoints Leila Alland as Interim Chief Medical Officer; Authorized Shares Raised to 300 Mill…
CRDF · Cardiff Oncology, Inc.
- Leadership change
- Other event
- Material agreement
- Materiality: high
On October 22, 2026, Cardiff Oncology's Chief Medical Officer Dr. Roger Sidhu separated from the company in a mutually agreed transition. Effective October 23, 2026, the company engaged Dr. Leila Alland as interim Chief Medical Officer under a consulting agreement through April 22, 2027 at a monthly fee of $35,000. On October 22, 2026, the company also filed a Certificate of Amendment increasing authorized common stock to 300,000,000 shares.
Source: SEC EDGAR, Form 8-K, Items 5.02, 5.03, 7.01, 9.01, accession 0001493152-26-048720.
Written from the filing by Shamburg Markets. Figures are as reported by the company.